Reduced phosphoinositide 3-kinase (p110α) activation increases the susceptibility to atrial fibrillation

American Journal of Pathology

Volumn 175, Issue 3, 2009, Pages 998-1009

  Pretorius, Lynette ^a,b   Du, Xiao Jun ^a   Woodcock, Elizabeth A ^a   Kiriazis, Helen ^a   Lin, Ruby C Y ^c   Marasco, Silvana ^d   Medcalf, Robert L ^b   Ming, Ziqiu ^a   Head, Geoffrey A ^a   Joon, Win Tan ^a   Cemerlang, Nelly ^a   Sadoshima, Junichi ^e   Shioi, Tetsuo ^f,h   Izumo, Seigo ^f,i   Lukoshkova, Elena V ^g   Dart, Anthony M ^a,d   Jennings, Garry L ^a   McMullen, Julie R ^a,j  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^h KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ Gilead   (United States)

^j NONE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENETIC LINKAGE; HEART ATRIAL FIBROSIS; HEART ATRIUM APPENDAGE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART FUNCTION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MICROARRAY ANALYSIS; MORPHOLOGY; MOUSE; MUTANT; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SINUS RHYTHM; TRANSGENIC ANIMAL;

EID: 70349309772     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090126     Document Type: Article

References (58)

1. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231-1266
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952 (Pubitemid 28446646)
3. Thrall G, Lane D, Carroll D, Lip GY: Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006, 119:448 e441-419
4. Lip GY, Tse HF: Management of atrial fibrillation. Lancet 2007, 370:604-618
5. Hagendorff A, Schumacher B, Kirchhoff S, Luderitz B, Willecke K: Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 1999, 99:1508-1515 (Pubitemid 29140919)
6. Temple J, Frias P, Rottman J, Yang T, Wu Y, Verheijck EE, Zhang W, Siprachanh C, Kanki H, Atkinson JB, King P, Anderson ME, Kupershmidt S, Roden DM: Atrial fibrillation in KCNE1-null mice. Circ Res 2005, 97:62-69
7. Zhang X, Chen S, Yoo S, Chakrabarti S, Zhang T, Ke T, Oberti C, Yong SL, Fang F, Li L, de la Fuente R, Wang L, Chen Q, Wang QK: Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell 2008, 135:1017-1027
8. Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW, 2nd, Ross J, Jr., Chien KR, Brown JH: Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest 1999, 103:1627-1634 (Pubitemid 29534356)
9. Kehat I, Heinrich R, Ben-Izhak O, Miyazaki H, Gutkind JS, Aronheim A: Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. Cardiovasc Res 2006, 70:543-554
10. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC, Jr., Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR, Bernstein KE: Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004, 165:1019-1032 (Pubitemid 39129307)
11. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B: Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am J Physiol Heart Circ Physiol 2005, 289:H1456-1467 (Pubitemid 41368987)
12. Adam O, Frost G, Custodis F, Sussman MA, Schafers HJ, Bohm M, Laufs U: Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007, 50:359-367 (Pubitemid 47064499)
13. Ogata T, Ueyama T, Isodono K, Tagawa M, Takehara N, Kawashima T, Harada K, Takahashi T, Shioi T, Matsubara H, Oh H: MURC, a muscle-restricted coiled-coil protein that modulates the Rho/ROCK pathway, induces cardiac dysfunction and conduction disturbance. Mol Cell Biol 2008, 28:3424-3436 (Pubitemid 351657104)
14. Heist EK, Ruskin JN: Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. Prog Cardiovasc Dis 2006, 48:256-269 (Pubitemid 43326301)
15. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002, 415:219-226 (Pubitemid 34059528)
16. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S: The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000, 19:2537-2548 (Pubitemid 30323543)
17. McMullen JR, Jennings GL: Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007, 34:255-262
18. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM, Izumo S: Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA: 2003, 100:12355-12360 (Pubitemid 37271564)
19. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, Mollica JP, Zhang L, Zhang Y, Shioi T, Buerger A, Izumo S, Jay PY, Jennings GL: Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA: 2007, 104:612-617 (Pubitemid 46123073)
20. McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S: The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway. J Biol Chem 2004, 279:4782-4793 (Pubitemid 38199073)
21. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH: Drug-induced atrial fibrillation. J Am Coll Cardiol 2004, 44:2117-2124
22. Kampinga HH, Henning RH, van Gelder IC, Brundel BJ: Beat shock proteins and atrial fibrillation. Cell Stress Chaperones 2007, 12:97-100
23. Mandal K, Torsney E, Poloniecki J, Camm AJ, Xu Q, Jahangiri M: Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg 2005, 79:865-871 (Pubitemid 40288738)
24. St Rammos K, Koullias GJ, Hassan MO, Argyrakis NP, Voucharas CG, Scarupa SJ, Cowte TG: Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc Surg 2002, 10:228-232
25. Afzal AR, Mandal K, Nyamweya S, Foteinos G, Poloniecki J, Camm AJ, Jahangiri M, Xu Q: Association of Met439Thr substitution in heat shock protein 70 gene with postoperative atrial fibrillation and serum HSP70 protein levels. Cardiology 2008, 110:45-52
26. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840-844
27. Wang TJ, Parise H, Levy D, D'Agostino RB, Sr., Wolf PA, Vasan RS, Benjamin EJ: Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292:2471-2477 (Pubitemid 39552671)
28. Lip GY, Varughese GI: Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005, 105:319-321 (Pubitemid 41613592)
29. Perrino C, Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA: Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 2006, 116:1547-1560 (Pubitemid 43911009)
30. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9:341-349 (Pubitemid 43668732)
31. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B: Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006, 441:366-370 (Pubitemid 44050203)
32. McMullen JR, Jay PY: PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 2007, 6:910-913
33. Yamamoto S, Yang G, Zablocki D, Liu J, Hong C, Kim SJ, Soler S, Odashima M, Thaisz J, Yehia G, Molina CA, Yatani A, Vatner DE, Vatner SF, Sadoshima J: Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest 2003, 111:1463-1474 (Pubitemid 38063279)
34. Du XJ, Gao XM, Wang B, Jennings GL, Woodcock EA, Dart AM: Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. Cardiovasc Res 2000, 48:448-454
35. Du XJ, Autelitano DJ, Dilley RJ, Wang B, Dart AM, Woodcock EA: beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000, 101:71-77
36. Head GA, Lukoshkova EV, Mayorov DN, van den Buuse M: Non-symmetrical double-logistic analysis of 24-h blood pressure recordings in normotensive and hypertensive rats. J Hypertens 2004, 22:2075-2085
37. Granelli-Piperno A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978, 148:223-234 (Pubitemid 8376490)
38. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL: Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003, 34:537-543 (Pubitemid 36206361)
39. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, Samuel CS: Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 2005, 46:412-418 (Pubitemid 41099178)
40. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S: Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055 (Pubitemid 38808328)
41. Ausma J, Coumans WA, Duimel H, Van der Vusse GJ, Allessie MA, Borgers M: Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation. Cardiovasc Res 2000, 47:788-796 (Pubitemid 30676292)
42. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA: Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104:174-180 (Pubitemid 32655834)
43. Tsai CT, Lai LP, Hwang JJ, Lin JL, Chiang FT: Molecular genetics of atrial fibrillation. J Am Coll Cardiol 2008, 52:241-250
44. Boixel C, Fontaine V, Rucker-Martin C, Milliez P, Louedec L, Michel JB, Jacob MP, Hatem SN: Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003, 42:336-344 (Pubitemid 36851427)
45. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342 (Pubitemid 350041472)
46. Fink RI, Kolterman OG, Griffin J, Olefsky JM: Mechanisms of insulin resistance in aging. J Clin Invest 1983, 71:1523-1535
47. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM: Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54:2360-2364 (Pubitemid 41134263)
48. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 2000, 106:473-481
49. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ: Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007, 100:1415-1427 (Pubitemid 46834754)
50. Roberts R: Genomics and cardiac arrhythmias. J Am Coll Cardiol 2006, 47:9-21
51. Borlak J, Thum T: Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J 2003, 17:1592-1608 (Pubitemid 37100061)
52. Brundel BJ, Van Gelder IC, Henning RH, Tuinenburg AE, Wietses M, Grandjean JG, Wilde AA, Van Gilst WH, Crijns HJ: Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol 2001, 37:926-932 (Pubitemid 32202465)
53. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S: Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999, 84:776-784 (Pubitemid 29181484)
54. Grammer JB, Bosch RF, Kuhlkamp V, Seipel L: Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J Cardiovasc Electrophysiol 2000, 11:626-633 (Pubitemid 30397533)
55. O'Neill BT, Kim J, Wende AR, Theobald HA, Tuinei J, Buchanan J, Guo A, Zaha VG, Davis DK, Schell JC, Boudina S, Wayment B, Litwin SE, Shioi T, Izumo S, Birnbaum MJ, Abel ED: A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab 2007, 6:294-306 (Pubitemid 47450187)
56. Chandy J, Nakai T, Lee RJ, Bellows WH, Dzankic S, Leung JM: Increases in P-wave dispersion predict postoperative atrial fibrillation after coronary artery bypass graft surgery. Anesth Analg 2004, 98:303-310 (Pubitemid 38139239)
57. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ, Jr., Cohn LH, Burstin HR: Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation 1996, 94:390-397 (Pubitemid 26266124)
58. Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ: Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009, 20:1026-1031